These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25358972)

  • 1. FHL2 expression and variants in hypertrophic cardiomyopathy.
    Friedrich FW; Reischmann S; Schwalm A; Unger A; Ramanujam D; Münch J; Müller OJ; Hengstenberg C; Galve E; Charron P; Linke WA; Engelhardt S; Patten M; Richard P; van der Velden J; Eschenhagen T; Isnard R; Carrier L
    Basic Res Cardiol; 2014; 109(6):451. PubMed ID: 25358972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.
    Friedrich FW; Wilding BR; Reischmann S; Crocini C; Lang P; Charron P; Müller OJ; McGrath MJ; Vollert I; Hansen A; Linke WA; Hengstenberg C; Bonne G; Morner S; Wichter T; Madeira H; Arbustini E; Eschenhagen T; Mitchell CA; Isnard R; Carrier L
    Hum Mol Genet; 2012 Jul; 21(14):3237-54. PubMed ID: 22523091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMYA5 is a novel interaction partner of FHL2 in cardiac myocytes.
    Stathopoulou K; Schnittger J; Raabe J; Fleischer F; Mangels N; Piasecki A; Findlay J; Hartmann K; Krasemann S; Schlossarek S; Uebeler J; Wixler V; Blake DJ; Baillie GS; Carrier L; Ehler E; Cuello F
    FEBS J; 2022 Aug; 289(15):4622-4645. PubMed ID: 35176204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2.
    Okamoto R; Li Y; Noma K; Hiroi Y; Liu PY; Taniguchi M; Ito M; Liao JK
    FASEB J; 2013 Apr; 27(4):1439-49. PubMed ID: 23271052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FHL2 binds calcineurin and represses pathological cardiac growth.
    Hojayev B; Rothermel BA; Gillette TG; Hill JA
    Mol Cell Biol; 2012 Oct; 32(19):4025-34. PubMed ID: 22851699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
    Riaz M; Park J; Sewanan LR; Ren Y; Schwan J; Das SK; Pomianowski PT; Huang Y; Ellis MW; Luo J; Liu J; Song L; Chen IP; Qiu C; Yazawa M; Tellides G; Hwa J; Young LH; Yang L; Marboe CC; Jacoby DL; Campbell SG; Qyang Y
    Circulation; 2022 Apr; 145(16):1238-1253. PubMed ID: 35384713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of dilated cardiomyopathy caused by FHL2 gene variant and a literature review].
    Yu C; Jia L; Hao C; Zuo B; Li W; Wang F; Guo J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Mar; 40(3):337-343. PubMed ID: 36854411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-and-a-half LIM domain protein 2 (FHL2) deficiency protects mice from diet-induced obesity and high FHL2 expression marks human obesity.
    Clemente-Olivo MP; Habibe JJ; Vos M; Ottenhoff R; Jongejan A; Herrema H; Zelcer N; Kooijman S; Rensen PCN; van Raalte DH; Nieuwdorp M; Eringa EC; de Vries CJ
    Metabolism; 2021 Aug; 121():154815. PubMed ID: 34119536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-and-a-half LIM domains proteins are novel regulators of the protein kinase D pathway in cardiac myocytes.
    Stathopoulou K; Cuello F; Candasamy AJ; Kemp EM; Ehler E; Haworth RS; Avkiran M
    Biochem J; 2014 Feb; 457(3):451-61. PubMed ID: 24219103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue.
    Crocini C; Arimura T; Reischmann S; Eder A; Braren I; Hansen A; Eschenhagen T; Kimura A; Carrier L
    Basic Res Cardiol; 2013 May; 108(3):349. PubMed ID: 23572067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac-specific LIM protein FHL2 modifies the hypertrophic response to beta-adrenergic stimulation.
    Kong Y; Shelton JM; Rothermel B; Li X; Richardson JA; Bassel-Duby R; Williams RS
    Circulation; 2001 Jun; 103(22):2731-8. PubMed ID: 11390345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel cardiac z-disc protein CEFIP regulates cardiomyocyte hypertrophy by modulating calcineurin signaling.
    Dierck F; Kuhn C; Rohr C; Hille S; Braune J; Sossalla S; Molt S; van der Ven PFM; Fürst DO; Frey N
    J Biol Chem; 2017 Sep; 292(37):15180-15191. PubMed ID: 28717008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription.
    Hua G; He C; Lv X; Fan L; Wang C; Remmenga SW; Rodabaugh KJ; Yang L; Lele SM; Yang P; Karpf AR; Davis JS; Wang C
    Cell Death Dis; 2016 Jul; 7(7):e2297. PubMed ID: 27415427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis.
    Wixler V; Cromme C; Retser E; Meyer LH; Smyth N; Mühlenberg K; Korb-Pap A; Koers-Wunrau C; Sotsios Y; Bassel-Duby R; Baeten D; Tak PP; Niederreiter B; Redlich K; Bertrand J; Skryabin BV; Ludwig S; Pap T
    Ann Rheum Dis; 2015 Dec; 74(12):2216-23. PubMed ID: 25125695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy.
    Rachmin I; Amsalem E; Golomb E; Beeri R; Gilon D; Fang P; Nechushtan H; Kay G; Guo M; Yiqing PL; Foo RS; Fisher DE; Razin E; Tshori S
    Int J Cardiol; 2015 Sep; 195():85-94. PubMed ID: 26025865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy.
    Olson TM; Doan TP; Kishimoto NY; Whitby FG; Ackerman MJ; Fananapazir L
    J Mol Cell Cardiol; 2000 Sep; 32(9):1687-94. PubMed ID: 10966831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy.
    Geier C; Perrot A; Ozcelik C; Binner P; Counsell D; Hoffmann K; Pilz B; Martiniak Y; Gehmlich K; van der Ven PF; Fürst DO; Vornwald A; von Hodenberg E; Nürnberg P; Scheffold T; Dietz R; Osterziel KJ
    Circulation; 2003 Mar; 107(10):1390-5. PubMed ID: 12642359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of FHL2 gene impaired ischemia-induced blood flow recovery by modulating circulating proangiogenic cells.
    Huang PH; Chen CY; Lin CP; Wang CH; Tsai HY; Lo WY; Leu HB; Chen JW; Lin SJ; Chu PH
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):709-17. PubMed ID: 23413425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
    J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.